Australia, NZ markets fall more than 3 percent

By
October 7, 2008 04:08

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Stock markets in Australia and New Zealand fell for a second day Tuesday and their currencies continued to drop against the US dollar after a plunge in US and European markets showed no let-up in the global financial crisis. The Australian benchmark S&P/ASX-200 index lost 3.27 percent shortly after opening. A day earlier, it hit a three-year low, losing 155 points to close down 3.3 percent. In New Zealand on Tuesday, the benchmark NZX-50 index was down 2.84 percent or 84.15 points at 2,964.23 shortly after midday local time (2300 GMT Monday), a fresh three-year low. The slide follows a 5.84 percent decline during trading on Friday and Monday. The slides come after stocks in the United States, Europe and Asia spiraled downward Monday, with the Dow falling below 10,000 for the first time since 2004.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS